Eli Lilly and Company ($LLY) Stock Forecast: Down 5.0% Today

What is Eli Lilly and Company?

Eli Lilly and Company (LLY) is a renowned pharmaceutical company known for its focus on neuroscience and other therapeutic areas. Today, LLY experienced a significant bearish movement in the stock market.

Why is Eli Lilly and Company going down?

LLY stock is down 5.0% on Apr 15, 2026 16:20

• LLY's stock took a hit today despite announcing the acquisition of Centessa Pharmaceuticals for $7.8 billion, a move aimed at bolstering its neuroscience pipeline. The market reaction might be due to various factors:
• The rebranding of FCB Health New York to Olixir New York by a leading advertising agency could have raised concerns about potential competition in the healthcare marketing sector, impacting investor sentiment towards LLY.
• The partnership between AC Immune and LLY to advance Alzheimer's therapy, with a substantial upfront payment and milestone potential, might have shifted focus away from LLY's core operations, leading to a bearish trend.
• The spotlight on another company's strong obesity drug pipeline and growth prospects in metabolic diseases could have diverted investor attention from LLY's strategic moves, contributing to the downward movement in its stock price.
• Overall, while LLY's acquisition news was positive for its long-term growth strategy, external market dynamics and developments in the healthcare sector likely influenced the bearish trend observed today.

LLY Price Chart

LLY Technical Analysis

LLY News

Omnicom Health rebrands FCB Health New York to Olixir New York

Omnicom Health has rebranded FCB Health New York to Olixir New York, a move that follows Omnicom's takeover of IPG and another recent rebranding of DDB Health to Remedy Edge. Linda Bennett and Kathleen Nanda will continue to lead Olixir New York as president and chief creative officer, respectively, building on FCB Health New York's legacy as a top medical marketing agency. The new name combines "elixir" with the "O" from Omnicom and is expected to expand globally after its U.S. launch.

https://www.mmm-online.com/news/omnicom-health-rebrands-fcb-health-new-york-to-olixir-new-york/

LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal

This article announces that Eli Lilly and Company (LLY) will acquire neuroscience biotech Centessa Pharmaceuticals for $7.8 billion. The acquisition aims to strengthen Lilly's pipeline in neuroscience, a key area of therapeutic focus.

https://www.msn.com/en-us/money/other/lly-to-buy-neuroscience-biotech-centessa-pharmaceuticals-in-7-8b-deal/ar-AA1ZVdhe?ocid=TobArticle&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1

Prothena Corp plc stock (IE00B91XRN20): Why does its biotech pipeline matter more now for investors?

Prothena Corp plc is a clinical-stage biotechnology company focusing on therapies for neurodegeneration and amyloidosis, targeting diseases like Alzheimer's and AL amyloidosis. The company's pipeline, including lead candidate birtamimab and partner asset prasinezumab, leverages proprietary technologies to address significant unmet medical needs. With a strategic emphasis on partnerships and a lean operating model, Prothena aims to deliver high returns to investors through potential blockbuster drug approvals, especially for its Nasdaq-listed ADR (PRTA).

https://www.ad-hoc-news.de/boerse/news/ueberblick/prothena-corp-plc-stock-ie00b91xrn20-why-does-its-biotech-pipeline/69158604

AC Immune secures CHF 10 million from Lilly to advance Alzheimer’s therapy

AC Immune, a biopharmaceutical company based in Lausanne, has amended its agreement with Eli Lilly to further develop Tau Morphomer small molecule candidates for Alzheimer's disease and other neurodegenerative conditions. The expanded collaboration, which includes new lead candidates, will provide AC Immune with a CHF 10 million upfront payment and additional milestone payments, potentially reaching over CHF 1.7 billion. This initiative leverages AC Immune's Morphomer platform, which designs small molecules to target pathological forms of the Tau protein, a key driver in neurodegeneration.

https://ggba.swiss/en/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy/

Amgen Inc. stock (US0311621009): Is its obesity drug pipeline strong enough to unlock new upside?

Amgen Inc. is highlighted as a biotech leader with a robust pipeline, particularly in metabolic diseases like obesity, positioning it for growth in the high-demand weight-loss therapy market. The company's core business model focuses on complex biologics, ensuring strong economic moats and stable revenue, while its strategic priorities include advancing experimental obesity drug MariTide. This analysis suggests Amgen offers defensive growth and potential market share gains for investors due to its diverse portfolio and focus on demographic tailwinds.

https://www.ad-hoc-news.de/boerse/news/ueberblick/amgen-inc-stock-us0311621009-is-its-obesity-drug-pipeline-strong/69155987

Trending Today

DocuSign Inc. ($DOCU) Stock Forecast: Up 5.0% Today

Fidelity National Information Services Inc. ($FIS) Stock Forecast: Up 5.1% Today

Salesforce.com Inc ($CRM) Stock Forecast: Up 5.2% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 7.5% Today

Lyft Inc. ($LYFT) Stock Forecast: Up 7.0% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.2% Today

Ingersoll-Rand plc (Ireland) ($IR) Stock Forecast: Down 6.9% Today

Datadog Inc. ($DDOG) Stock Forecast: Up 9.2% Today

Westinghouse Air Brake Technologies Corporation ($WAB) Stock Forecast: Down 5.1% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 5.8% Today

Eli Lilly and Company Price History

01.03.2026 - LLY Stock was up 5.3%

• The bullish movement in LLY stock can be attributed to the announcement of its acquisition of Centessa Pharmaceuticals, focusing on advancing treatments for sleep-wake disorders. This strategic move was likely well-received by investors, leading to positive market performance for LLY.
• The increase in Pfizer's stock price and positive Q4 earnings report may have also contributed to the overall bullish sentiment in the pharmaceutical sector, indirectly impacting LLY's stock performance.
• The quarterly distribution declaration by Direxion Daily LLY Bull 2X Shares could have further boosted investor confidence in LLY, signaling potential returns for shareholders.
• The investigation into the sale of Centessa Pharmaceuticals by Kahn Swick & Foti, LLC may have caused some uncertainty in the market, but the overall market reaction seems to have focused more on the growth prospects of LLY through the acquisition.

05.01.2026 - LLY Stock was down 5.2%

• The bearish movement in Eli Lilly & Co (LLY) stock could be attributed to profit-taking by investors after a recent rally or market correction.
• Despite being identified as a promising growth stock with strong fundamentals, including earnings and sales growth, investors might have reacted to broader market sentiment or sector-specific concerns.
• The focus on pharmaceutical stocks like Eli Lilly & Co (LLY) could have shifted due to a stem cell specialist going public via a SPAC merger, drawing attention away from traditional pharmaceutical companies.
• Additionally, a positive stock price prediction for Waste Management and growth potential for Hershey might have diverted investor interest away from Eli Lilly & Co (LLY) temporarily, impacting its stock performance.

05.01.2026 - LLY Stock was down 5.8%

• The decision by CVS Health to replace Amgen and Lilly's bone disease therapies with lower-cost biosimilars is likely to have negatively impacted Lilly's stock price, potentially decreasing revenue from these products.
• The market's response to Eikon Therapeutics' Nasdaq debut, despite an initial lower share price, might have shifted investor focus away from established pharmaceutical companies like Lilly, contributing to the bearish movement.
• CVS Health's emphasis on cost-effective alternatives over branded treatments could have prompted investor doubts regarding the competitiveness of Lilly's products, leading to the bearish trend.
• Overall, the transition towards more economical healthcare options and the introduction of new players in the pharmaceutical industry might have affected investor perception of established companies such as Eli Lilly, resulting in the bearish market movement.

15.03.2026 - LLY Stock was down 5.0%

• LLY's stock took a hit today despite announcing the acquisition of Centessa Pharmaceuticals for $7.8 billion, a move aimed at bolstering its neuroscience pipeline. The market reaction might be due to various factors:
• The rebranding of FCB Health New York to Olixir New York by a leading advertising agency could have raised concerns about potential competition in the healthcare marketing sector, impacting investor sentiment towards LLY.
• The partnership between AC Immune and LLY to advance Alzheimer's therapy, with a substantial upfront payment and milestone potential, might have shifted focus away from LLY's core operations, leading to a bearish trend.
• The spotlight on another company's strong obesity drug pipeline and growth prospects in metabolic diseases could have diverted investor attention from LLY's strategic moves, contributing to the downward movement in its stock price.
• Overall, while LLY's acquisition news was positive for its long-term growth strategy, external market dynamics and developments in the healthcare sector likely influenced the bearish trend observed today.

18.02.2026 - LLY Stock was down 5.6%

• Positive Phase 2 results reported by a competitor in oncology and immunology may have overshadowed Eli Lilly's performance, leading investors to shift their focus towards the competitor's promising pipeline.
• Mosaic's strategic move into rare earths extraction could have diverted investor attention away from traditional pharmaceutical stocks like Eli Lilly, impacting its stock price negatively.
• Livforsakringsbolaget Skandia Omsesidigt's decision to reduce its stake in Eli Lilly could have signaled concerns about the company's future growth prospects, contributing to the bearish movement.
• Overall, the combination of positive developments in other companies' pipelines and shifting investor sentiment towards different sectors may have influenced the bearish trend in Eli Lilly's stock today.

17.02.2026 - LLY Stock was down 5.2%

• Despite a recent increase, Eli Lilly's stock has encountered a downward trend, potentially linked to analysts' downgrade, hinting at challenges ahead.
• The launch of Eli Lilly's weight-loss pill, Orforglipron, might not be sufficient to counteract concerns arising from the downgrade.
• Positive results from Pfizer on their advanced CDK4 inhibitor, Atirmociclib, could have diverted investor attention to Pfizer's promising pipeline, impacting Eli Lilly's stock negatively.
• Investors could be reassessing Eli Lilly's competitive position in the pharmaceutical sector, especially compared to companies like Pfizer, with robust drug candidates like Atirmociclib.

17.02.2026 - LLY Stock was down 5.7%

• Eli Lilly's stock faced a bearish movement today following a series of downgrades from analysts, including concerns about valuation and emerging competitors in the oral GLP-1 market.
• Despite a strong run-up in the past year and the anticipation of the launch of its new weight-loss pill, orforglipron, later this year, the stock has been downgraded, indicating potential headwinds ahead.
• The downgrades come at a time when the pharmaceutical industry is seeing advancements from competitors, potentially impacting Eli Lilly's market position and growth prospects.
• The overall sentiment towards Eli Lilly remains mixed, with analysts highlighting both the company's recent positive earnings and the challenges it may face in the near future, leading to the bearish movement in the stock today.

04.01.2026 - LLY Stock was up 9.2%

• Eli Lilly's shares surged by 10% following the company's impressive fourth-quarter 2025 results and optimistic 2026 forecast, driven by the success of its weight-loss drugs Zepbound and Mounjaro.
• A Buy rating from Goldman Sachs for Eli Lilly further boosted investor confidence, highlighting the stock's attractiveness and maintaining a target price of USD 1145.
• The strong performance of Eli Lilly amidst a positive market reaction underscores the company's robust growth in the weight-loss drug market, setting a bullish tone for its future prospects.

04.01.2026 - LLY Stock was up 5.4%

• Eli Lilly reported impressive Q4 results, surpassing revenue and profit expectations, driven by the success of its drugs Zepbound and Mounjaro, leading to a significant stock surge.
• The company's robust 2026 revenue guidance, exceeding analyst estimates, indicates strong growth prospects and market confidence in its product pipeline.
• Positive market sentiment towards Eli Lilly contrasts with concerns in the pharmaceutical sector, highlighted by Pfizer's modest 2026 guidance and sustainability worries regarding its dividend payout ratio.
• Eli Lilly's performance showcases the importance of consistent innovation and successful product launches in driving stock value, setting it apart from competitors like Novo Nordisk.

04.01.2026 - LLY Stock was up 8.8%

• LLY's stock surged by 10% following the company's better-than-expected Q4 2025 results and optimistic 2026 forecast, driven by the success of weight-loss drugs Zepbound and Mounjaro.
• The positive market reaction can be attributed to Lilly's robust revenue growth of 42.6% year-over-year and adjusted earnings per share exceeding analyst estimates.
• This bullish trend for LLY contrasts with Novo Nordisk's recent 15% stock drop due to a conservative sales outlook, highlighting the importance of strong performance and growth forecasts in the pharmaceutical industry.
• Analysts, such as those at Goldman Sachs, continue to view Eli Lilly favorably, maintaining a Buy rating amidst the company's impressive financial results and market outlook.

09.01.2026 - LLY Stock was down 5.2%

• The acquisition of Orna by Eli Lilly for up to $2.4 billion may have stirred concerns among investors about potential risks and uncertainties related to the deal.
• Criticism from the FDA regarding Novo Nordisk's obesity pill advertisement, indirectly affecting competitors like Eli Lilly in the GLP-1 market, could have contributed to a negative sentiment in the sector.
• The market response to Pfizer's Q4 results, despite positive strides in its obesity drug segment, may have led to a broader bearish trend in the pharmaceutical industry, impacting stocks such as Eli Lilly.
• Eli Lilly's strategic shift towards diversification beyond obesity drugs through investments in circular RNA therapies could have triggered uncertainty among investors about the company's future direction and challenges in entering new markets.

09.01.2026 - LLY Stock was down 5.1%

• Eli Lilly's acquisition of Orna Therapeutics for up to $2.4 billion was met with mixed market sentiment, potentially contributing to the bearish movement.
• Despite the positive news of diversification into circular RNA therapies, investors may have concerns about the hefty price tag of the acquisition impacting Lilly's short-term financials.
• The market may be reacting to the broader industry news, such as Pfizer's lukewarm Q4 results and CVS Health Corporation facing pressure from proposed Medicare reimbursement rates, creating a cautious atmosphere for pharmaceutical stocks.
• Overall, while the acquisition signals Eli Lilly's strategic focus on expanding its portfolio, short-term market dynamics and industry challenges could be influencing the bearish trend in LLY stock.